Designing Around Aldehyde Oxidase: Structural Modifications in Brain-Penetrant Heterocycles: Structure–Activity Relationship, Strategies and Mechanistic Insights

Abstract

This review critically examines the metabolic liability of aldehyde oxidase (AO), an important consideration in drug discovery, particularly for CNS drug candidates that must cross the blood-brain barrier (BBB) while remaining metabolically stable. The review compares the structural modification strategies adopted to overcome AO-mediated metabolism in brain-penetrant heterocyclic compounds, with emphasis on the mechanistic rationale and level of evidence, and the translational scope of each approach. Structure–activity relationship (SAR) strategies examined include strategic fluorination, ortho-substitution, and scaffold-hopping methods, notably switching a pyridine ring to a pyrimidine. Analysis of experimental, computational, and case-study literature indicates that site-specific substitutions (especially at the C2 position of azaheterocycles) consistently reduce AO-mediated oxidation, and that strategic fluorination modulates physicochemical properties relevant to BBB penetration by altering pKa, lipophilicity, and interactions with efflux transporters. An alternative kinetic reduction of metabolic turnover is the incorporation of deuterium at oxidized sites. Crystallography, molecular docking, and quantum chemical modelling have been used to study the mechanistic aspects of the AO reaction and its dynamics of binding to the active site, which led to the elucidation of AO active site architecture and rational drug design. Integrated SAR strategies are demonstrated in case studies with β-secretase (BACE1) inhibitors, GluN2B selective negative allosteric modulators, and c-Met kinase inhibitors, which led to the discovery of potent, brain-penetrant molecules with better PK properties. The problems that still lie ahead are interspecies variability in AO activity, underprediction of AO clearance in vitro, and lack of clinical validation data. Increased attention to multiparametric optimization processes involving both AO metabolic liability and CNS penetration, using enhanced computational models and standardized in vitro phenotyping tools, would be warranted for future research.